# Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion

> **NCT00150085** · PHASE4 · TERMINATED · sponsor: **Novartis** · enrollment: 50 (actual)

## Conditions studied

- Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients

## Interventions

- **DRUG:** cyclosporine micro-emulsion

## Key facts

- **NCT ID:** NCT00150085
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-02
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2011-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00150085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00150085, "Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00150085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*